Our Company | UCB
UCB's Global Corporate Website

A global biopharma company, focusing on neurology and immunology.

Our business is strong. Total revenue grew to €5.8 billion in 2021. We are approximately 8,600 people in all four corners of the globe, inspired by patients and driven by science.

 

Our vision

 

UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science.

UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives

Our-company-banner-V2
Our-company-Therese

Our strategy

We recognise that radical changes are taking place in the eco-system of care and that we need to evolve accordingly to deliver on our vision. The key element of our evolution is to focus on the delivery of increased patient value.

There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process.

That is why we support patient groups who provide valuable services to patient communities and understand what matters to people living with severe diseases.

We believe in partnership. Our scientists collaborate with leading researchers from academia and industry to advance science and deliver the solutions patients need. Our open approach to innovation equips us to meet today’s biggest healthcare challenges.

Discover more about us

a

More than 70 nationalities

Our history

Looking ahead, we are building on this position of strength and preparation the next wave of future medicines and solutions, driving future growth and creating value for patients.

In the early years of the 21st century, UCB began to transform into a pure biopharma company. 

Significant milestones included the acquisition of Celltech, a British biotech firm in 2004, and then German pharma company, Schwarz Pharma, in 2006.

A significant breakthrough came in the 1980s when UCB registered Zyrtec© - a novel antihistamine product. A blockbuster was born, helping to further raise the profile of the company. 

A second blockbuster - Keppra© - was launched in the 1990s, spurring further global growth. 

A significant breakthrough came in the 1980s when UCB registered Zyrtec© - a novel antihistamine product. A blockbuster was born, helping to further raise the profile of the company. 

A second blockbuster - Keppra© - was launched in the 1990s, spurring further global growth. 

UCB was created in Brussels by Emmanuel Janssen in the 1920s.

The company expanded and entered the US market in the 1930s.

Our scientists' first therapeutic breakthroughs came in the 1950s, followed in the 1960s by visionary research into the field of biotechnology.

"Traditionally, science is connected to the patient. We want to connect patients to science. This is the business model of today and tomorrow."

- Jean-Christophe Tellier

 

Click to read our 90-year book